Who
Alison Moore
President and CEO
Company insider
Files Form 4 as: President and CEO, Codexis; Director, Artiva Biotherapeutics; Chief Technical Officer, Allogene Therapeutics.
In numbers
- Trades disclosed
- 77
- Buys
- 0
- Sells
- 18
- Bought
- $0
- Sold
- $9.8M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 13 Mar 2019
- Last trade
- 12 Oct 2026
- Last filed
- 14 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Oct 2026filed 14 Oct 2026 | CDXS CodexisChemicals | SEC FORM 4 Sold | $8,6196,335 at $1.36 | filing |
| 10 Sep 2026filed 14 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,250 at $0.00 | filing |
| 10 Sep 2026filed 14 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,250 at $0.00 | filing |
| 8 Sep 2026filed 8 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,750 at $0.00 | filing |
| 8 Sep 2026filed 8 Sep 2026 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,750 at $0.00 | filing |
| 23 Feb 2026filed 25 Feb 2026 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —993,000 at $0.00 | filing |
| 23 Feb 2026filed 25 Feb 2026 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —993,000 at $0.00 | filing |
| 6 Feb 2026filed 9 Feb 2026 | CDXS CodexisChemicals | SEC FORM 4 Sold | $5,0013,826 at $1.31 | filing |
| 6 Feb 2026filed 9 Feb 2026 | CDXS CodexisChemicals | SEC FORM 4 Sold | $5,0123,826 at $1.31 | filing |
| 13 Nov 2025filed 17 Nov 2025 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 13 Nov 2025filed 17 Nov 2025 | CDXS CodexisChemicals | SEC FORM 4 Code A | —85,000 at $0.00 | filing |
| 13 Oct 2025filed 15 Oct 2025 | CDXS CodexisChemicals | SEC FORM 4 Sold | $16K6,239 at $2.51 | filing |
| 24 Jun 2025filed 26 Jun 2025 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,750 at $0.00 | filing |
| 5 Feb 2025filed 7 Feb 2025 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —161,250 at $0.00 | filing |
| 5 Feb 2025filed 7 Feb 2025 | CDXS CodexisChemicals | SEC FORM 4 Code A | —26,875 at $0.00 | filing |
| 21 Oct 2024filed 22 Oct 2024 | ARTV Artiva Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,500 at $0.00 | filing |
| 10 Oct 2024filed 10 Oct 2024 | CDXS Codexisoption or derivative · Chemicals | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 10 Oct 2024filed 10 Oct 2024 | CDXS CodexisChemicals | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 11 Jun 2024filed 13 Jun 2024 | CDXS CodexisChemicals | SEC FORM 4 Code A | —30,120 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | CDXS CodexisChemicals | SEC FORM 4 Code A | —34,602 at $0.00 | filing |
News
Codexis (NASDAQ:CDXS) and Revvity (NYSE:RVTY) Head-To-Head ComparisonCDXS · themarketsdaily.com · 19 Oct 2026
0 headlines in the last 90 days name Alison Moore; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.